Table 6.

Chronic NR-ANX-C pretreatment reduced EW-induced anxiety behavior in bright and dark arena.

Treatment group	Number of entries into bright arena	Time spent in bright arena (s)	Rears in bright arena	Rears in dark arena	Duration of immobility (s)
EW control	1.7 ± 0.2	13.9 ± 2.1	1.0 ± 0.3	11.6 ± 1.8	19.6 ± 4.9
Alprazolam (0.08 mg/kg)	3.0 ± 0.2**	25.7 ± 1.5*	3.0 ± 0.2*	20.7 ± 1.6**	0.9 ± 0.4**
NR-ANX-C (10 mg/kg)	2.3 ± 0.2	22.0 ± 3.2	3.0 ± 0.4*	12.8 ± 1.4	4.2 ± 2.9**
NR-ANX-C (20 mg/kg)	2.7 ± 0.3*	27.2 ± 3.3*	3.2 ± 0.3*	13.2 ± 1.3	2.8 ± 0.7**
NR-ANX-C (40 mg/kg)	2.8 ± 0.3*	30.7 ± 3.6**	7.0 ± 0.9**	18.8 ± 2.5*	1.2 ± 4.1**

Values are mean ± SEM; Statistical analysis by One-way ANOVA followed by Dunnett's Multiple Comparison test. *P < .05; **P < .01.